

2-11-03

RP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Stefano BONGRANI, et al.

SERIAL NO: New US PCT application based on PCT/EP00/07184

GAU:

FILED: Herewith

EXAMINER:

FOR: 2-AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF GLAUCOMA

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).


CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBOLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)

533176000000

23 JAN 2007

SHEET 1 OF 1

Form PTO 1449 (Modified)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. 217836US0PCT		SERIAL NO. 10/030114 New US PCT application based on PCT/EP00/07184	
LIST OF REFERENCES CITED BY APPLICANT			APPLICANT Stefano BONGRANI, et al.						
			FILING DATE Herewith		GROUP				
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	AA	5 236 907	08/17/93	Ryuzo UENO et al.					
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								
	AM								
	AN								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION		YES	NO
	AO	2 123 410	02/01/84	GB					No
	AP	96 29065	09/26/96	WO					No
	AQ	0 009 702	04/16/80	EP					No
	AR								
	AS								
	AT								
	AU								
	AV								
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)									
	AW	Carmine MORISCO et al.: "Hemodynamic effects of graded oral doses of a new dopaminergic analogue CHF 1035 in patients with congestive heart failure" JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, no. SPEC. ISSUE, page 128A 1995							
	AX								
	AY								
	AZ					<input type="checkbox"/> Additional References sheet(s) attached			
Examiner						Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									